Those alterations are copy number variations, or CNVs: large-scale changes in the number of copies carried by specific genomic regions, ranging from a handful of genes to entire chromosome arms. In cancer, an amplified region may deliver extra doses of oncogenes that drive uncontrolled proliferation, while a deleted region can erase tumor suppressor genes that normally restrain growth. A subtler event, copy-neutral loss of heterozygosity, substitutes one parental chromosome copy with a duplicate of the other, leaving total dosage unchanged while quietly erasing genetic diversity. Because such changes accumulate stepwise over a tumor’s lifetime, its CNV landscape is effectively a record of evolution, with successive generations of subclones each carrying a nested set of aberrations inherited from their progenitors. Reading that clonal architecture is a central ambition of cancer genomics: it reveals which alterations appeared early and are shared by every malignant cell, and which arose late, potentially fueling aggressive behavior or drug resistance.

The most direct way to measure copy number is to sequence tumor DNA, either in bulk or, at far greater cost and effort, from single cells. But DNA methods have blind spots: bulk sequencing averages its signal across whatever mixture of malignant, immune and stromal cells happens to populate a biopsy, diluting copy number calls in impure samples, while single-cell DNA sequencing remains expensive and technically exacting. RNA, by contrast, is captured routinely and in extraordinary detail by two technologies that have transformed cancer biology: single-cell RNA sequencing, or scRNA-seq, which profiles thousands of individual cells one by one, and spatial transcriptomics, which measures gene activity across intact tissue sections while preserving the physical location of every data point. Because the abundance of a gene’s transcripts broadly tracks the number of DNA copies encoding it, chromosome-scale copy number states can in principle be reconstructed from expression profiles — an approach pioneered by tools such as inferCNV, which smooth expression signals along the genome so that broad waves of excess or deficit become visible.

In practice, the inference is fragile. Expression levels fluctuate for reasons that have nothing to do with dosage: transcription fires in bursts, sequencing samples each cell’s transcripts sparsely and stochastically, and cell-type-specific gene programs can masquerade as chromosomal gains or losses. Most existing tools also lean on a supply of confidently normal, diploid cells within the same dataset to define the baseline against which tumor cells are judged — a luxury that tumor-pure samples and cell line experiments rarely offer. The Genome Medicine authors catalog the resulting shortcomings bluntly: slow speed, high memory consumption, reduced accuracy when no diploid reference is available, lower sensitivity at low read counts, and no support for clonal tree construction. Those weaknesses become acute with high-definition spatial platforms such as Visium HD, whose dense, fine-grained datasets can overwhelm software designed for smaller experiments — which is precisely why copy number analysis had never before been extended to this technology.

FastCNV attacks the problem with two core statistical strategies. Instead of hunting for diploid cells within each sample, the software pools diploid references across samples, constructing a far more stable baseline for what normal gene dosage looks like along each chromosome. Within each sample, it then aggregates similar spots or cells that carry few sequencing reads into composite “meta spots” or “meta cells,” deliberately merging weak observations to strengthen the statistical signal available for detecting copy number events. This aggregation tames the noise that plagues shallowly sequenced data without sacrificing the resolution needed to keep distinct cell populations apart. The package also builds a clonality tree automatically, arranging the inferred subclones into an evolutionary diagram that shows how the detected aberrations relate to one another — a task that previously demanded separate analyses or manual curation. And it was engineered for thrift: the analyses presented in the study ran on a modest workstation equipped with 20 CPU cores and 64 gigabytes of memory.

To measure accuracy, the researchers assembled 117 cancer cell line samples for which both scRNA-seq data and bulk whole-exome sequencing, which reads copy number directly from DNA, were available. Cell lines made an ideal proving ground: consisting entirely of malignant cells, they provide a clean ground truth unblurred by stromal or immune bystanders. FastCNV’s inferred copy number profiles correlated strongly with the DNA-derived standard, with a median correlation above 0.75 across the panel — a striking result given that the tool never sees tumor DNA at all. Crucially, the study reports a significant improvement over other established methods such as inferCNV, both in overall accuracy and in behavior at low sequencing depth, where sparse counts cause lesser tools to falter. The result demonstrates that copy number information lies recoverable within even noisy single-cell transcriptomes, provided the statistical machinery is built to reach it.

Speed and resource benchmarks told a similar story. FastCNV ran several times faster than competing methods while using less memory — so much so that benchmarking the alternatives, including tools named xClone and Numbat, had to be moved to a server built around an AMD EPYC 9654 processor, largely because their pre-processing steps demand substantially greater computational resources. FastCNV’s own analyses, by contrast, ran comfortably on the laboratory workstation. For working researchers, the practical meaning is that copy number inference no longer requires a high-performance computing cluster or overnight waits. It becomes a routine step that slots inside a standard analysis pipeline, including one of the field’s most common chores: deciding whether the cells in a single-cell experiment are malignant or merely healthy bystanders.

The most striking demonstration came from spatial data. FastCNV is, according to the team, the first method able to analyze CNVs from Visium HD, a high-definition spatial transcriptomics technology that records genome-wide expression across intact tissue at fine spatial resolution. Applied to breast cancer samples profiled with Visium HD, the software identified tumor subclones tightly related to different histologies — the distinct appearances tissue takes under the microscope — effectively drawing a map that links specific genetic aberrations to tumor progression. The evolutionary history reconstructed purely from expression data lined up with the visible architecture of the tissue itself. That convergence carries real weight, because tumor geography is clinically meaningful: regions with different evolutionary histories can behave differently under therapy, and knowing which aberrations localize where offers a route to studying how tumors invade, diversify and acquire resistance within their native spatial context rather than in dissociated, position-blind cell suspensions.

The clinical logic runs deeper still. Copy number aberrations are comparatively stable hallmarks of malignancy that persist even as a cell’s expression program shifts with its surroundings, which makes them a dependable way to flag tumor cells among normal bystanders — one of the core uses the authors cite, alongside characterizing clonal architecture. Because FastCNV requires neither matched normal DNA nor diploid reference cells from within the same sample, it can in principle be applied wherever expression data already exist, including retrospective cohorts sitting in public repositories. Combined with spatial coordinates, copy number inference lets researchers chart not just which cells are cancerous but which branch of the tumor’s family tree they occupy, layering genomics onto the tissue landscapes pathologists have read for more than a century. The authors position FastCNV explicitly as a step toward personalized medicine, in which a patient’s tumor could be screened for clonal structure rapidly and inexpensively as part of routine molecular diagnostics.

FastCNV is written as an R package, the lingua franca of computational biology, and is freely available on GitHub, while the underlying article is published open access in Genome Medicine. The work was led by co-first authors Gadea Cabrejas and Marine Sroussi under the joint supervision of Clarice Groeneveld and Aurélien de Reyniès, with funding from, among others, the French Ministry of Health, the French Ministry of Research, the French National Cancer Institute, the French League Against Cancer and the European Union’s Horizon Europe program. The authors conclude that FastCNV represents “a significant improvement on existing R methods” for copy number detection from spatial and single-cell data “in terms of speed, memory usage, sensitivity and accuracy,” highlighting its potential to advance cancer research and personalized medicine. Its arrival lands as spatial transcriptomics marches from specialist laboratories toward mainstream cancer research and, eventually, clinical pathology, with datasets growing faster than the software built to interpret them. If independent groups confirm the tool’s performance on their own cohorts, the tedious arithmetic of copy number inference could fade into the background of every single-cell and spatial analysis — leaving researchers free to follow the evolutionary stories their tumors are telling.

Skin stem cells, essential for continual skin regeneration and repair, have now been shown to retain a remarkably persistent memory of inflammatory events. This revelation emerged from a collaborative study led by computational biologist Dana Pe’er, PhD, and stem cell biologist Elaine Fuchs, PhD. The research dissected the chromatin accessibility landscape of skin stem cells following inflammatory stimuli, demonstrating that particular regions within the DNA maintain an “open” configuration for over a year, even as cells repeatedly divide to replenish the epidermis. This epigenetic persistence suggests that stem cells are not merely passive rebuilders but are biochemically programmed to recall prior insults and respond more rapidly upon re-exposure.

The team employed advanced machine learning models trained to recognize patterns in DNA sequences associated with long-term epigenetic alterations. Their computational approach pinpointed sequence motifs that encode the heritable nature of these chromatin states, revealing that the genome intrinsically directs methylation and chromatin dynamics across successive generations of cells. Such findings underscore a paradigm in which inflammatory memory is molecularly inscribed within the genome’s regulatory architecture, poised to influence how skin tissue adapts—or maladapts—with age and repeated environmental challenges. These insights raise compelling questions about the relationship between persistent inflammation, tissue dysfunction, and age-associated diseases, marking a new frontier in dermatological biology.

In parallel, the MSK team undertook an unprecedented genomic survey of nearly 50,000 cancer patients spanning almost 450 cancer types, leveraging data from MSK-IMPACT®, their robust tumor sequencing platform. The comprehensive analysis unveiled a striking complexity in mutation behavior contingent on the cancer context. While certain mutations act as primary oncogenic drivers in their canonical tumor types, fueling early tumor initiation and present ubiquitously across malignant cells, these very same mutations display divergent roles when found in atypical cancers. They tend to emerge later in tumor evolution, are restricted to subclonal populations, and have attenuated oncogenic functions. This nuanced understanding challenges the conventional “one mutation, one action” dogma and demands refined classification frameworks in precision oncology, tailoring therapeutic decisions to the specific genetic and cellular milieu of each tumor.

Beyond elucidating driver mutation dynamics, the extensive dataset provided fresh angles on cancer genetics, highlighting the influence of fusion genes in cancers presenting at an early age as well as revealing correlations between patients’ genetic ancestry and responsiveness to immunotherapies such as T cell receptor (TCR) treatments. The transparent availability of this enormous dataset through MSK’s cBioPortal for Cancer Genomics empowers the global research community to further dissect and harness these data to optimize personalized cancer care.

In a revealing investigation into cancer cells’ innate ability to evade immune surveillance, researchers from John Maciejowski’s lab at the Sloan Kettering Institute identified the protein BAF (barrier-to-autointegration factor) as a critical mediator in masking chromosomal instability signals. Tumors often exhibit chromosomal instability characterized by improper chromosome segregation during cell division, generating micronuclei—small extranuclear DNA bodies prone to rupture, which should alert intrinsic immune defenses. BAF functions by coating the exposed micronuclear DNA upon rupture and recruiting TREX1, an exonuclease that degrades cytosolic DNA fragments, thereby attenuating the activation of the DNA sensor cGAS and preventing the elicitation of cancer-directed immune responses.

Strikingly, depletion of BAF unleashes cGAS’s access to the micronuclear DNA, triggering a potent antitumor immune response. Furthermore, simultaneous ablation of TREX1 amplifies this effect, confirming that both components collaboratively suppress innate immune detection pathways. This discovery exposes a novel immune evasion mechanism exploited by chromosomally unstable cancers and identifies BAF as a promising therapeutic target to disrupt tumor immune camouflage, potentially enhancing responses to immunotherapies.

The final revelation from MSK concerns the epigenetic underpinnings of cellular differentiation, addressing a fundamental question in developmental biology: are enhancer elements—the genomic switches that activate gene expression programs—primed before cell fate commitment? Researchers at the Sloan Kettering Institute employed cutting-edge methodologies—including CRISPR-based chromatin interrogation, single-cell transcriptomics, and chromatin accessibility assays—to interrogate human embryonic stem cells (ESCs). Their work established that enhancers associated with fully differentiated cells are pre-marked within pluripotent ESCs well before lineage specification.

These pre-established enhancers bear distinctive molecular markers, indicating a chromatin landscape configured to anticipate future gene activation. Moreover, these “pre-enhancer” regions could autonomously initiate transcriptional programs independent of external differentiation cues. This prefiguring mechanism provides a crucial framework for understanding how pluripotent cells are epigenetically equipped to embark on diverse developmental trajectories, facilitating refined strategies for cellular reprogramming and regenerative medicine.

Co-corresponding author Julian Pulecio, PhD, emphasizes that decoding these chromatin features offers novel opportunities to model gene regulatory networks, improve the precision of in vitro differentiation protocols, and elucidate how dysregulation of enhancers contributes to disease states such as cancer. Collectively, this body of research from MSK offers transformative perspectives on the interplay between genetics, epigenetics, and cell biology, heralding a new era of personalized medicine and targeted therapies.

By interrogating the layers of genomic and epigenomic regulation across health and disease, these studies illuminate the profound intricacies of cellular memory, oncogenic heterogeneity, immune interaction, and developmental priming. They underscore how interdisciplinary approaches—combining computational biology, advanced sequencing, and molecular genetics—are key to unlocking the full potential of precision oncology and regenerative science. As these discoveries continue to ripple through the biomedical community, they promise to catalyze innovative treatments and deepen our grasp of human biology at its most fundamental levels.

Subject of Research:
Skin stem cell inflammatory memory, cancer mutation heterogeneity, cancer immune evasion mechanisms, and embryonic stem cell chromatin priming.

Article Title:
Memorial Sloan Kettering Uncovers Epigenetic Memory in Skin, Mutation Complexity in Cancer, Tumor Immune Camouflage, and Developmental Enhancer Priming

News Publication Date:
2024

Web References:
Data from MSK cBioPortal for Cancer Genomics: https://www.cbioportal.org
Articles in Science, Cancer Cell, Molecular Cell, and Cell Genomics journals (specific articles referenced in the original MSK summary)

References:
Original research studies published by teams led by Dana Pe’er, Elaine Fuchs, Chaitanya Bandlamudi, Michael Berger, John Maciejowski, Yanyang Chen, Roshan Xavier Norman, and Julian Pulecio at Memorial Sloan Kettering Cancer Center and affiliates.

Image Credits:
Memorial Sloan Kettering Cancer Center

Neuroblastoma, originating from immature nerve cells, predominantly affects infants and young children. Despite advances in surgical techniques, chemotherapy regimens, and stem cell therapies, the prognosis for high-risk neuroblastoma remains grim, with survival rates stubbornly below 60%. This dismal outlook stems in part from the tumor’s notorious heterogeneity and the current scarcity of reliable biomarkers that can stratify patients effectively, guiding precision therapies.

Traditional molecular markers such as MYCN amplification and ALK mutations, while clinically informative, cover only subsets of patients and often require intricate or expensive testing methodologies. These limitations have spurred an urgent quest for more universally applicable and interpretable prognostic signatures. The recent study answers this call by integrating vast sequencing datasets with cutting-edge computational approaches, revealing a richer molecular tapestry of neuroblastoma.

At the heart of this research is an enhanced spatial temporal Support Vector Machine (stSVM) algorithm, adeptly applied to bulk RNA sequencing (RNA-seq) data from over 1,200 neuroblastoma patients. This machine learning model sifted through thousands of gene expression profiles to identify 528 genes tightly correlated with patient survival outcomes. This expansive gene set offers a panoramic view of the genetic drivers underlying disease aggressiveness.

To distill actionable biomarkers from this extensive gene pool, the team employed Weighted Gene Co-expression Network Analysis (WGCNA), a method that elucidates patterns of gene co-regulation and pinpoints central “hub” genes driving network behavior. This refined analysis spotlighted 11 hub genes with outsized influence on neuroblastoma biology: AURKA, BLM, BRCA1, BRCA2, CCNA2, CHEK1, E2F1, MAD2L1, PLK1, RAD51, and notably, RFC3.

Among these, RFC3 emerged as a particularly compelling prognostic marker. Elevated expression of RFC3 was strongly associated with poor patient survival and intriguingly linked to suppressed natural killer (NK) cell activity, suggesting a tumor mechanism of immune evasion. This finding hints that RFC3 might not simply be a bystander gene but an active participant in sculpting the tumor microenvironment to favor cancer progression.

Beyond correlating gene expression with clinical outcomes, the study probed how these hub genes influence responsiveness to chemotherapy drugs routinely used in neuroblastoma treatment. Intriguingly, tumors exhibiting high RFC3 levels demonstrated increased sensitivity to vincristine and cyclophosphamide, two cornerstone agents in pediatric oncology protocols. This dual prognostic and predictive utility positions RFC3 as a potential biomarker to both assess risk and guide therapeutic choices.

To deepen their mechanistic understanding, the researchers also examined single-cell RNA sequencing (scRNA-seq) data, allowing resolution of gene expression at the level of individual tumor and immune cells. This granular analysis confirmed elevated RFC3 expression predominantly in epithelial and myeloid cell subpopulations of patients with poorer survival outcomes. Moreover, these patients exhibited reduced infiltration of CD8+ T cells, another critical component of the anti-tumor immune response. Such immune profiling provides valuable insight into the interplay between tumor genetics and host immunity.

The study’s integrative pipeline—combining machine learning, bulk and single-cell transcriptomics, immune profiling, and co-expression network analysis—exemplifies modern systems biology approaches applied to pediatric cancer research. This multidisciplinary methodology uncovers complex molecular interdependencies that traditional statistical analyses frequently overlook, offering a more holistic view of neuroblastoma pathobiology.

Dr. Yupeng Cun, senior investigator on the project, highlights the transformative potential of this research: “Our comprehensive approach reveals novel biomarkers like RFC3 that not only predict clinical outcomes but also indicate likely responses to standard chemotherapy agents. By fusing computational models with multi-omics data, we uncover molecular patterns that can ultimately enhance patient stratification and individualized treatment.”

These findings mark an important milestone for precision medicine in childhood cancers. As a biomarker, RFC3 stands out for its multifaceted role—informing prognosis, reflecting immune landscape alterations, and hinting at chemotherapy responsiveness. Clinicians in the future could leverage RFC3 expression to identify high-risk neuroblastoma patients early, tailoring treatment intensity and monitoring strategies accordingly to improve survival chances.

Furthermore, the platform developed by this research team could be adapted to other aggressive cancers, expanding its impact beyond neuroblastoma to benefit a broader spectrum of oncologic diseases. Continued work integrating additional omics layers—such as proteomics and epigenomics—and further experimental validation will be vital to translating these insights into clinical tools.

This study underscores the growing importance of artificial intelligence and machine learning technologies in decoding cancer complexity. By revealing genetic architects of neuroblastoma and their relationships with the immune system and drug sensitivity, researchers are stepping closer to conquering a formidable pediatric malignancy that has long evaded definitive prognostic clarity.

As the field progresses, personalized oncology for children with neuroblastoma may soon incorporate biomarkers like RFC3 as routinely measured clinical tools. These advances promise not only improved risk assessment but also more nuanced, effective therapeutic regimens that minimize toxicity and maximize survival—a long-sought goal in pediatric cancer care.

The promise held by such integrative, AI-driven biomarker discovery efforts ignites hope that tailored treatments could markedly improve outcomes, sparing children unnecessary side effects while targeting their tumors with precision. For families confronting neuroblastoma, these advances bring new optimism fueled by the power of genomic medicine and computational innovation.

In sum, this pioneering research not only reveals critical molecular insights but also charts a pragmatic path toward clinical application, heralding a new era of prognostic sophistication and treatment personalization in pediatric neuroblastoma.

Subject of Research:
Not applicable

Article Title:
Identification of Prognostic Biomarkers in Gene Expression Profile of Neuroblastoma Via Machine Learning

News Publication Date:
27-May-2025

Web References:
http://dx.doi.org/10.1002/pdi3.70009

References:
10.1002/pdi3.70009

Image Credits:
Pediatric Discovery

Keywords:
Neuroblastoma, Pediatric Oncology, Machine Learning, Biomarkers, Gene Expression, RFC3, Immune Evasion, Chemotherapy Sensitivity, Single-cell RNA Sequencing, Weighted Gene Co-expression Network Analysis, Precision Medicine